Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Operating Expenses: 2016-2025

Historic Other Operating Expenses for Seres Therapeutics (MCRB) over the last 2 years, with Sep 2025 value amounting to $736,000.

  • Seres Therapeutics' Other Operating Expenses was N/A to $736,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Seres Therapeutics' Other Operating Expenses stood at $736,000, which was up 297.84% from $185,000 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Other Operating Expenses registered a high of $3.6 million during Q1 2023, and its lowest value of -$346,000 during Q4 2022.
  • In the last 3 years, Seres Therapeutics' Other Operating Expenses had a median value of $2.1 million in 2023 and averaged $2.1 million.
  • In the last 5 years, Seres Therapeutics' Other Operating Expenses slumped by 157.19% in 2022 and then surged by 877.12% in 2023.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Other Operating Expenses stood at $605,000 in 2021, then plummeted by 157.19% to -$346,000 in 2022, then skyrocketed by 877.12% to $2.1 million in 2023, then reached $3.5 million in 2024, then reached $736,000 in 2025.
  • Its last three reported values are $736,000 in Q3 2025, $185,000 for Q2 2025, and $2.2 million during Q1 2025.